Pharmacological Characterisation of Pseudocerastes and Eristicophis Viper Venoms Reveal Anticancer (Melanoma) Properties and a Potentially Novel Mode of Fibrinogenolysis
Open Access
- 27 June 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 6896
Abstract
Venoms are a rich source of potential lead compounds for drug discovery, and descriptive studies of venom form the first phase of the biodiscovery process. In this study, we investigated the pharmacological potential of crude Pseudocerastes and Eristicophis snake venoms in haematological disorders and cancer treatment. We assessed their antithrombotic potential using fibrinogen thromboelastography, fibrinogen gels with and without protease inhibitors, and colourimetric fibrinolysis assays. These assays indicated that the anticoagulant properties of the venoms are likely induced by the hydrolysis of phospholipids and by selective fibrinogenolysis. Furthermore, while most fibrinogenolysis occurred by the direct activity of snake venom metalloproteases and serine proteases, modest evidence indicated that fibrinogenolytic activity may also be mediated by selective venom phospholipases and an inhibitory venom-derived serine protease. We also found that the Pseudocerastes venoms significantly reduced the viability of human melanoma (MM96L) cells by more than 80%, while it had almost no effect on the healthy neonatal foreskin fibroblasts (NFF) as determined by viability assays. The bioactive properties of these venoms suggest that they contain a number of toxins suitable for downstream pharmacological development as candidates for antithrombotic or anticancer agents.Keywords
Funding Information
- TALENTO Program by the Regional Madrid Government (2018-T1/BIO-11262)
- National Institute for Medical Research Development (942485)
- PDRF Phase II Batch-V (NRPU No.20-3891)
- Australian Research Council (DP190100304)
This publication has 31 references indexed in Scilit:
- MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistanceMolecular Cancer, 2014
- Thrombin generation, fibrin clot formation and hemostasisTransfusion and Apheresis Science, 2008
- Distribution of low molecular weight platelet aggregation inhibitors from snake venomsToxicon, 2007
- Snake venom fibrin(ogen)olytic enzymesToxicon, 2005
- Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymesToxicon, 2003
- Apoptosis and melanoma chemoresistanceOncogene, 2003
- Characterization of two platelet aggregation inhibitor-like polypeptides from viper venomPeptides, 1992
- Comparison of venoms from two subspecies of the false horned viper (Pseudocerastes persicus)Toxicon, 1986
- Mode of neuromuscular blocking action of a toxic phospholipase A2 from Pseudocerastes fieldi (Field's horned viper) snake venomToxicon, 1983
- Isolation and characterization of the main toxic fraction from the venom of the false horned viper (Pseudocerastes fieldi)Toxicon, 1982